Polaryx Therapeutics Receives Both Rare Pediatric Disease and Orphan Drug Designations for the Treatment of Niemann Pick Disease Types A and B With PLX-300

PARAMUS, N.J., Dec. 18, 2020 -- (Healthcare Sales & Marketing Network) -- Polaryx Therapeutics, Inc., a biotech company developing small molecule therapeutics for lysosomal storage disorders, announced today that it has received from the U.S. Food and Dru... Biopharmaceuticals, Neurology, FDA Polaryx Therapeutics, Niemann Pick Disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news